Evidence map›Paper›PMID 39150487›Full record

ArticleEuropean radiology2025

Glucose metabolic rate from four-dimensional [

Akihiro Inoue, Michinobu Nagao, Koichiro Kaneko, Atsushi Yamamoto, Yurie Shirai, Ohno Toshihiro, Akiko Sakai, Risa Imakado, Shuji Sakai

Abstract read
PubMed Publisher
In one paragraph

Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Akihiro InoueDepartment of Diagnostic Imaging and Nuclear Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Michinobu NagaoDepartment of Diagnostic Imaging and Nuclear Medicine, Tokyo Women's Medical University, Tokyo, Japan. nagao.michinobu@twmu.ac.jp.ORCID http://orcid.org/0000-0001-6049-8857
Koichiro KanekoDepartment of Diagnostic Imaging and Nuclear Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Atsushi YamamotoDepartment of Diagnostic Imaging and Nuclear Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Yurie ShiraiDepartment of Diagnostic Imaging and Nuclear Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Ohno ToshihiroDepartment of Diagnostic Imaging and Nuclear Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Akiko SakaiDepartment of Cardiology, Tokyo Women's Medical University, Tokyo, Japan.
Risa ImakadoDepartment of Cardiology, Tokyo Women's Medical University, Tokyo, Japan.
Shuji SakaiDepartment of Diagnostic Imaging and Nuclear Medicine, Tokyo Women's Medical University, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesOn MATERIALS AND

methodsA total of 100 patients with cardiac sarcoidosis (CS) and 67 patients with cancer who underwent four-dimensional FDG PET/CT were enrolled. The lesions with a standardized uptake value (SUV) ≥ 2.7 on the standard scan were included as active lesions in the analysis. SUV and MR

resultsA total of 90 sarcoidosis lesions from 44 CS patients (18 males, 63.4 ± 12.2 years) and 87 malignant lesions from 57 cancer-bearing patients (32 males, 65 ± 14 years) were analyzed. SUV and MR

conclusionMR CLINICAL RELEVANCE STATEMENT: MR KEY POINTS: Active sarcoid lesions are sometimes associated with FDG accumulation and should be differentiated from malignant lesions. SUV and metabolic rate of glucose (MRglc) strongly positively correlated, and MRglc could differentiate sarcoid and malignant lesions. MRglc allows for accurate evaluation and staging of malignant lesions.

Indexed as

CardiomyopathiesFluorodeoxyglucose F18GlucoseNeoplasmsPositron Emission Tomography Computed TomographySarcoidosisAgedDiagnosis, DifferentialFemaleHumansMaleMiddle AgedRadiopharmaceuticalsSensitivity and SpecificityFluorodeoxyglucose F18GlucoseRadiopharmaceuticalsFDG-PETMalignant tumorMRglcPatlak reconstructionSarcoidosis

Identifiers

PMID39150487

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.